Latest News Archive

Please select Category, Year, and then Month to display items

Celebrating 25 years of the UFS Business School

29 November 2024 | Story Anthony Mthembu | Photo Tania Allan

Business School 25 Year Celebration — Some of the guests and staff members of the UFS Business School who attended the 25th anniversary celebration of the school.

To commemorate its 25^th anniversary, the Business School at the University of the Free State (UFS) held a celebratory event on the UFS Bloemfontein Campus on 22 November 2024.

Prof Frans Prinsloo, acting Dean of the Faculty of Economic and Management Sciences (EMS) at the UFS who attended the event, said, “The occasion is not just a celebration of the passing of time, but it’s also an opportunity for us to reflect on the values, achievements, and aspirations that have shaped the journey of the UFS Business School.” The event, which was regarded as a ‘momentous milestone’, was also attended by Prof Nicolene Barkhuizen, Director of the UFS Business School, Prof Frederick Fourie and Prof Bennie Anderson – founding members of the Business School, as well as Prof Tienie Crous and Prof Hendri Kroukamp, who are former deans of EMS.

A walk down memory lane

In his opening address, Prof Prinsloo reflected on the growth of the Business School over the past 25 years and highlighted some of the achievements of the staff that make up the Business School. However, the highlight of the event for many in the audience was the trip down memory lane by the founding members of the Business School as well as the former deans of the faculty.

In their address, Profs Fourie and Anderson shared some of their fondest memories and experiences as they worked towards putting together the Business School. For instance, Prof Fourie indicated that in order to ensure that the syllabus was of high quality, the founding members had to travel overseas and learn from several institutions, such as Harvard Business School.

In addition, Profs Fourie and Anderson spoke extensively about their pride in the Business Management and Leadership (BML) programme, offered by the Business School. According to Prof Fourie, the degree was the brainchild of Prof Anderson, who for several reasons wanted to consider working adults who might not have had experience in school learning. As such, they consider the BML programme as one of their most special achievements, given its impact. Furthermore, Prof Crous and Prof Kroukamp also shared their memories of being part of the institution, and specifically the Business School.

Forging ahead for another 25 years

In the pursuit of 25 more years, Prof Barkhuizen indicated that the school is aiming to achieve success with several projects. These include staff and student exchanges in order to optimise the experience of both stakeholders. “Even though we have a global reach, it is important for us to apply it locally,” she said. In addition, Prof Barkhuizen highlights that for the Business School to continue serving the needs of its unique student clientele, it needs to become more agile. As such, it will continuously reinvent its programmes with the input of its stakeholders. For instance, she indicated that the school is looking at implementing joint qualification offerings, among other things.

As the event ended, Prof Barkhuizen said that she was, “so proud of the progress made by the Business School; it has been a journey to get here, but this function today taught me to never give up hope and not to give up on one’s dreams”.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept